Psilocybin therapy in Ontario: what exists and who can access it

What does psilocybin therapy in Ontario actually look like? As of 11 October 2026, it is not a clinical service you can book. Health Canada says that no therapeutic product containing psilocybin is approved in Canada or elsewhere, and that the production, sale and possession of magic mushrooms are illegal. What exists is research, and a short list of federal exceptions that run through a regulated practitioner and Health Canada. The answer is the same whether you are asking about psilocybin therapy in Toronto, Ottawa, Kingston or anywhere else in the province, because the rules are federal and the trials are what vary by city.

This article describes what we could confirm from primary sources: Health Canada pages, the federal regulations, the ClinicalTrials.gov registry, and Ontario government pages. It says what we looked for and did not find. It does not recommend any clinic, provider or product, and it is not a way to get psilocybin.

Is psilocybin therapy available in Ontario?

Not as an approved treatment. Health Canada states that at this time there are no approved therapeutic products containing psilocybin, and that it has not assessed the safety, efficacy and quality of products containing it. It adds that some initial clinical trials have shown promising results but that the evidence is currently limited. Our own reading of that evidence starts with the depression trials.

The same page names three ways that people may legally reach psilocybin for a medical reason, each needing a regulated health care practitioner: clinical trials, the Special Access Program, and individual subsection 56(1) exemptions (Health Canada). It calls clinical trials the most appropriate and effective way to advance research with psilocybin. How provincial and city rules fit in is covered in our guide to the law in Ontario.

Which psilocybin clinical trials are running in Ontario?

This is where most of what exists sits. We queried the ClinicalTrials.gov API (version 2.0.5, data timestamp 9 October 2026) for studies with psilocybin as an intervention and an Ontario location. It returned 31 studies, and every one lists at least one Ontario site. By overall registry status, 10 were recruiting, 1 was enrolling by invitation, 3 were not yet recruiting, 8 were active but not recruiting, 7 were completed, 1 was suspended and 1 had an unknown status.

The table lists all 31 as the registry showed them on 11 October 2026. “Status” is the overall status of the study. Individual sites can differ: for example, one bipolar II study is recruiting overall while its Ottawa and Toronto sites were each listed as not yet recruiting. The “Ontario sites” column gives cities only.

What does the registry list tell you, and what does it not?

It shows that research is active in Ontario: the Centre for Addiction and Mental Health is lead sponsor of 8 of the 31 studies and University Health Network of 5, with others led by Unity Health Toronto, Sunnybrook, The Ottawa Hospital’s research institute, McMaster University and individual investigators. A few are company-sponsored. Several sites in the registry are hospitals, and a few are commercial research organizations; all are listed as registered study sites, not as places to receive treatment.

It does not show that anyone can walk in, that a study is accepting a given person, or that the intervention works. Each protocol sets its own eligibility, many are small phase 1 or 2 studies, and several concern imaging or mechanism rather than treatment. Registry entries can also lag the real situation: one study is listed with an unknown status, and the registry data we queried was dated two days before our check. Health Canada’s page advises people interested in a trial to talk to their health care provider. We do not list contact routes for any study.

Can anyone in Ontario get psilocybin outside a trial?

In law, yes, but only through a practitioner and Health Canada, and not on request. Under the Special Access Program, only a regulated health care practitioner can submit a request, individuals cannot apply directly, requests are decided case by case and approval is not guaranteed (Health Canada). Under an individual section 56(1) exemption, the Minister of Health may exempt a person or activity for scientific, medical or public interest purposes. Health Canada says these should generally be pursued only after trials and the SAP have been considered or found unavailable or unsuitable, and requests need a letter of support from a medical practitioner.

We found no published count of how many such authorizations exist for Ontario patients, and we do not claim a number. The broader picture is in our guide to psilocybin-assisted therapy in Canada.

One timing caution applies. The federal Controlled Substances Regulations (SOR/2025-242) came into force on 1 October 2026, and Health Canada updated its psilocybin page on 20 October 2026. The one wording change we found is in its clinical-trials section, which now names those Regulations as the authorization needed to sell psilocybin for clinical testing (Health Canada). The rest of the page, including its description of the Special Access Program and exemptions, reads as before. Check the Health Canada pages for the current wording of each route before relying on a description of it, including ours.

Has the College of Physicians and Surgeons of Ontario issued guidance?

We could not find any. On 11 October 2026 we searched the CPSO website for “psilocybin” and for “psychedelic”, and each search returned no results. That is a limited check: a site search is not a review of every policy and advice document, and the College may address the subject in material that the search does not index. A physician in Ontario who is asked about psilocybin should ask the College directly, and a patient should not read our finding as the College’s position.

Does OHIP or the Ontario Drug Benefit cover psilocybin therapy?

We found no coverage and no mention of it. The Ontario government’s What OHIP covers page (updated 22 April 2026) does not mention psilocybin. It lists services considered experimental, and prescription drugs provided in non-hospital settings, among those OHIP does not cover. The Ontario Drug Benefit page (updated 18 August 2026) says drugs that are not listed on the formulary or approved through the Exceptional Access Program are not covered, and it also does not mention psilocybin.

We therefore cannot point to any public OHIP or ODB pathway for psilocybin therapy, and a person asking about costs should ask the study team, practitioner or Ministry of Health directly. Within a clinical trial, costs are set by the study; we did not verify what any particular study charges or pays.

What is not legally available in Ontario?

Anything outside the routes above. Health Canada says activities with magic mushrooms are illegal unless authorized by Health Canada, for example through a licence, exemption or regulation (Health Canada). That covers storefronts, mail-order sellers, retreats and private “therapy” services that supply psilocybin without a trial, an SAP authorization or an exemption. It stays true however a service describes itself, and whether or not it has a website, a storefront or a professional-looking intake form. For the penalties and how enforcement has worked, see our guide to the law in Ontario.

There is a practical risk as well as a legal one. An unauthorized service is outside the trial and Special Access Program safeguards described above, and nothing about its product has been assessed by Health Canada. Health Canada notes that the safety, efficacy and quality of products containing psilocybin have not been assessed, and lists anxiety and panic attacks among its negative mental effects. See our safety page and are magic mushrooms safe?. We name no such service, and we point readers to none.

Shroomverse sells mushroom products. That is why this article is explicit: nothing we sell is a lawful route to therapy, and a trial listing is not a recommendation of anything.

What is unsettled or unknown?

• Whether the CPSO has any guidance. A site search found none, and we did not check other College materials.
• How often the Special Access Program and individual exemptions are granted for psilocybin, in Ontario or elsewhere. We found no official figures.
• How Health Canada’s guidance on the access routes reads under the 1 October 2026 regulations. Its psilocybin page, updated on 20 October 2026, names them only in its clinical-trials section and does not otherwise discuss them.
• Which of the 31 listed studies are open to any given person. Registry status is not an eligibility statement.
• Whether psilocybin will be approved or funded. No approval exists, and we found no OHIP or ODB statement. For one US filing and its bearing on Canada, see what COMP360 means for Canada.

How can you check the current position?

Read Health Canada’s psilocybin page and its Special Access Program page. Search ClinicalTrials.gov for psilocybin and your province, which is the same query we used. Then ask a regulated health care practitioner about your own situation, and a Canadian lawyer for a legal question. If you or someone near you is in crisis, call or text 9-8-8 or call 911, and see our safety page for further resources.

Shroomverse sells mushroom products. This article is general information about the law and clinical research. It is not medical or legal advice, and it does not recommend any product, provider or clinic.